Four Zhongguancun Life Science Park Companies Shine in Dual Prestigious Biopharma Rankings

Jul 03, 2024 18:28 CST Updated 18:28

InnoCare

Innovative Drug Developer

BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs

Edigene

Genome Editing Technology Developer

Recently,Top 100 List of Innovative Chinese Biomedical Enterprises in 2023, Fourth Medicines Innovation Jishi AwardHeavyweight Release.

Enterprises in Zhongguan Village Life Science ParkInnoCare、BeOne MedicinesAndBoya jiyinSuccessfully selected for "Top 100 List of China's Biomedical Enterprise Innovation Power in 2023”；Co-founder, Chairman and CEO of InnoCareDr. Jisong CuiAwarded "Top Ten Drug Innovation Leaders of the Year"PharmaronAwarded "Top Ten Drug Innovation Service Agencies of the Year"”，BeOne MedicinesBGB-30813 Tablets Awarded "Drug Innovation Pioneer of the Year"”。

Estimated reading time: 2 minutes

"Top 100 List of Innovative Chinese Biomedical Enterprises in 2023"Based on the theoretical framework of the "Enterprise Innovation Capability Evaluation Index System" by the Ministry of Science and Technology, and in accordance with the characteristics of the biopharmaceutical industry, the innovation capability evaluation indicators are summarized as follows:"Innovation Investment" "Innovation Achievements" "Intellectual Property" "Innovation-Driven"Four Dimensions and 11-Indicator System: A Comprehensive Evaluation of Innovative Pharmaceutical Companies Based on Annual Reports, CDE Review Data, Third-Party Patent Statistics, and Public Data.

During the selection event, MNI continued to refer to the international classification methods for biopharmaceutical enterprises, dividing the list into four sub-lists: "Top 10 Innovative Big Pharma Companies in China," "Top 30 Innovative Small Molecule Drug Companies in China," "Top 30 Innovative Antibody Drug Companies in China," and "Top 30 Innovative New Technology Drug Companies in China."

InnoCare, a company in the park, has been successfully selected for the "Top 30 Most Innovative Chinese Small Molecule Drug Enterprises in 2023," BeOne Medicines has been successfully selected for the "Top 30 Most Innovative Chinese Antibody Drug Enterprises," and Boya jiyin(Beijing)Biotechnology Co., Ltd. has been successfully selected for the "Top 30 Most Innovative Chinese New Technology Drug Enterprises."

"4th Drug Innovation Jishi Award Selection"The event was hosted by the Securities Times and featured a total of 2 drug awards, 2 company awards, 2 individual awards, and 1 service organization award. Among them, Dr. Jisong Cui, co-founder, chairman, and CEO of InnoCare, was named one of the "Top Ten Annual Drug Innovation Leaders"; BeOne Medicines Ltd. won the "Top Ten Annual Drug Innovation Service Organizations" award; and BeOne Medicines' BGB-30813 tablet received the "Annual Drug Innovation Pioneer Award."

It is reported that,BGB-30813 is a DGKζ inhibitor,For the treatment of advanced or metastatic solid tumors。In terms of the competitive landscape for the DGKζ target, there are currently only four DGKζ inhibitors under research and development globally. Apart from BeOne Medicines' BGB-30813, these include Astellas' ASP1570 (Phase I/II), Bayer's BAY 2965501 (Phase I), and BMS' DGKα/DGKζ Inhibitor (Phase I).